Covaxin receives GMP certificate from Hungary, says Bharat Biotech

New Delhi, August 05 : Indigenous coronavirus disease (Covid-19) vaccine Covaxin, on Thursday, received a certificate of Good Manufacturing Practice (GMP) compliance from the Hungarian authorities. Vaccine maker Bharat Biotech announced this milestone via social media.

 

 

The Hyderabad-based vaccine maker said that with this approval, Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the COVID-19 pandemic.

 

The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.

 

 

 

The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorizations and certificates of good manufacturing practice, the Hyderabad-based vaccine maker said.

 

Bharat Biotech intends to submit documentation for Emergency Use Authorization (EUA) in several additional countries worldwide.

 

“The recognition complements our commitment to driving world-class innovation and being a frontrunner in the research and development of vaccines,” the firm said.

.

.